open access
Should local treatment of breast ductal carcinoma in situ be the same as the treatment of early invasive breast cancer
open access
Abstract
Heterogenicity of breast ductal carcinoma in situ gives rise to opposing proposals concerning its treatment — ranging from attempts to recommend the watch and wait strategy in low risk forms ending with the currently binding standards of treatment of DCIS in the way identical as early invasive cancer in the high risk. Arguments for the treatment of ductal carcinoma in situ in the same way as patients with early invasive cancer have been presented. These arguments comprise: unknown natural history of untreated DCIS, high risk of undervaluation of the invasive component in the core-needle biopsy, the increase of recurrence risk with the progress of time, lack of verified separators of the groups with the risk of adverse course of the disease, the results of the clinical studies confirming the justification of combined local treatment and the proof that the clinical course of DCIS is the same as early invasive breast cancer, and, first and foremost, the fact that there are no clinical studies which could justify a limitation of the treatment scope.
Abstract
Heterogenicity of breast ductal carcinoma in situ gives rise to opposing proposals concerning its treatment — ranging from attempts to recommend the watch and wait strategy in low risk forms ending with the currently binding standards of treatment of DCIS in the way identical as early invasive cancer in the high risk. Arguments for the treatment of ductal carcinoma in situ in the same way as patients with early invasive cancer have been presented. These arguments comprise: unknown natural history of untreated DCIS, high risk of undervaluation of the invasive component in the core-needle biopsy, the increase of recurrence risk with the progress of time, lack of verified separators of the groups with the risk of adverse course of the disease, the results of the clinical studies confirming the justification of combined local treatment and the proof that the clinical course of DCIS is the same as early invasive breast cancer, and, first and foremost, the fact that there are no clinical studies which could justify a limitation of the treatment scope.
Keywords
DCIS — breast ductal carcinoma in situ, cancer heterogenicity, local treatment, watch and wait strategy, clinical studies
About this articleTitle
Should local treatment of breast ductal carcinoma in situ be the same as the treatment of early invasive breast cancer
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Other materials agreed with the Editors
Pages
74-78
Published online
2017-08-24
Page views
658
Article views/downloads
818
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2017;67(1):74-78.
Keywords
DCIS — breast ductal carcinoma in situ
cancer heterogenicity
local treatment
watch and wait strategy
clinical studies
Authors
Sylwia Grodecka-Gazdecka